BIG PHARMA WATCH: NEW STUDY FINDS PRICE HIKES DRIVEN BY QUEST FOR HIGHER PROFITS, NOT R&D
Analysis of Multiple Sclerosis Drug Pricing Undercuts Drug Makers’ Bogus “Innovation” Rhetoric A new study published in the American Academy of Neurology finds the staggering price of medications to treat multiple sclerosis (MS), a rare neurological disorder, is driven largely by profit motivations – not research and development (R&D). These findings undermine Big Pharma’s…